BRAF and melanoma: To test the effect of BRAF inhibitors (BRAFi; that is, vemurafenib—PLX4031 and dabrafenib—GSK2118436) on RIPK4, we used A375 and WM266.4 melanoma cells, which carry the BRAFV600E and BRAFV600D mutations, respectively (Supplementary Data, Figure S1) and express RIPK4 [27], and as a reference to BRAFWT cells: BLM (melanoma) and LoVo (colorectal cancer).